The p53 pathway is a central apoptotic regulator. Deregulation of the Rb/E2F pathway occurs in a majority of tumors, resulting in both unrestrained proliferation and enhanced apoptosis sensitivity via p53-dependent and independent mechanisms. However, the mechanisms coupling the p53 and Rb/E2F pathways remain incompletely understood. We report that ASPP2/ 53BP2L , a p53/p73-binding protein that promotes p53/p73-dependent apoptosis, is an E2F target gene. The ASPP2/ 53BP2L promoter was identified and ectopic expression of transcription-competent E2F-1 (E2F-2 and E2F-3) stimulated an ASPP2/ 53BP2L promoter-luciferase reporter. Mutational analysis of the ASPP2/ 53BP2L promoter identified E2F-binding sites that cooperate for E2F-1 induction and basal repression of ASPP2/ 53BP2L . Moreover, endogenous ASPP2/ 53BP2L levels increased after E2F-1 expression, and E2F-1 bound the endogenous ASPP2/ 53BP2L promoter after chromatin immunoprecipitation. Typical for an E2F target, ASPP2/ 53BP2L expression was maximal in early S-phase. Thus, ASPP2/ 53BP2L is downstream of E2F, suggesting that it functions as a common link between the p53/p73 and Rb/ E2F apoptotic pathways.
The p53 pathway is a central apoptotic regulator. Deregulation of the Rb/E2F pathway occurs in a majority of tumors, resulting in both unrestrained proliferation and enhanced apoptosis sensitivity via p53-dependent and independent mechanisms. However, the mechanisms coupling the p53 and Rb/E2F pathways remain incompletely understood. We report that ASPP2/ 53BP2L , a p53/p73-binding protein that promotes p53/p73-dependent apoptosis, is an E2F target gene. The ASPP2/ 53BP2L promoter was identified and ectopic expression of transcription-competent E2F-1 (E2F-2 and E2F-3) stimulated an ASPP2/ 53BP2L promoter-luciferase reporter. Mutational analysis of the ASPP2/ 53BP2L promoter identified E2F-binding sites that cooperate for E2F-1 induction and basal repression of ASPP2/ 53BP2L . Moreover, endogenous ASPP2/ 53BP2L levels increased after E2F-1 expression, and E2F-1 bound the endogenous ASPP2/ 53BP2L promoter after chromatin immunoprecipitation. Typical for an E2F target, ASPP2/ 53BP2L expression was maximal in early S-phase. Thus, ASPP2/ 53BP2L is downstream of E2F, suggesting that it functions as a common link between the p53/p73 and Rb/ E2F apoptotic pathways. 
Introduction
An important determinant of our ability to treat cancers rests on the observation that tumor cells often have an enhanced apoptotic sensitivity compared to normal cells. 1 The p53 apoptotic pathway is a central mediator of the apoptotic response. 2 Additionally, deregulation of the Rb/E2F pathway also occurs in a majority of human tumors, resulting in both unrestrained proliferation as well as promotion of apoptosis via p53-dependent and p53-independent mechanisms. [3] [4] [5] Thus, understanding the molecular linkage between cellular proliferation and sensitivity to apoptotic inputs in cancer cells is one of the most fundamental, yet incompletely understood, issues in oncology today.
The p53 tumor suppressor belongs to a transcription factor family of structurally related proteins including p73 and p63. 2, 6 Diverse cellular stresses (such as deregulated oncogenes or genotoxic damage) activate p53; however, what factors favor p53-mediated apoptosis (versus other outcomes such as cell cycle arrest) is an incompletely understood and highly complex process dependent on cellular context. p53-induced apoptosis occurs primarily through transactivation of proapoptotic target genes, 2 although transcriptional repression as well as transcription-independent functions may also play roles. [7] [8] [9] [10] [11] Cell context can influence p53 target gene specificity by affecting p53 covalent modifications or through complex protein-protein interaction networks 2, 12, 13 (and references within). Moreover, p73 and p63 directly or indirectly cooperate with p53 to trigger apoptosis. [14] [15] [16] [17] Understanding the mechanisms that modulate the p53 family will provide important insight into the cellular context favoring the apoptotic response.
Apoptosis Stimulating Protein of p53-2 (ASPP2), also referred to as 53BP2L, encoded by TP53BP2, [18] [19] [20] enhances damage-induced apoptosis 21, 22 through selective stimulation of p53 transactivation of proapoptotic target genes. 19 Recently, ASPP2/ 53BP2L and its homologue ASPP1 were additionally shown to enhance the apoptotic function of p73 and p63 by selective stimulation of proapoptotic target genes. 23 The carboxy-terminus of ASPP2, originally named 53BP2, 18 interacts with the wild-type, but not mutant, p53 core domain. 24, 25 This physical association between ASPP proteins and the conserved core domain of p53 family members appears necessary for full sensitization of cells to apoptotic inputs. 19, 23 Given the important functions of ASPP2/ 53BP2L , it is not surprising that it may be subject to complex regulation dependent on cell context. 22 However, the mechanisms regulating ASPP2/ 53BP2L remain poorly understood. The E2F family of transcription factors plays an important role in simultaneously promoting both cell proliferation and cell death. The 'activating' E2Fs (E2F-1, E2F-2, E2F-3) are important for controlling gene expression in late G1/early Sphase in addition to promoting apoptosis -particularly in the case of E2F-1. 3, 4, [26] [27] [28] [29] Entry into the cell cycle is therefore accompanied by sensitization to apoptotic inputs. In tumors that have not completely disabled the apoptotic pathway, this apoptosis sensitization may provide the 'therapeutic window' that allows chemotherapy to selectively kill cancer cells. 1 The Rb/E2F pathway cooperates with the p53 pathway at least in part by transactivation of ARF, although it is not clear how strictly ARF is required to mediate p53 function. [30] [31] [32] [33] [34] [35] [36] E2F-1 also promotes apoptosis via parallel pathways such as by transactivation of p73. [37] [38] [39] However, a common link coupling the Rb/E2F and p53/p73 pathways to promote sensitivity to apoptotic signals has not been described.
In this report, we present evidence that ASPP2/ 53BP2L is a direct E2F target gene. These findings suggest a common link between the p53/p73 and the Rb/E2F apoptotic pathways and provide insight into a possible unifying mechanism of how these pathways cooperate.
Results

ASPP2/ 53BP2L promoter has features of an E2F target gene
Previous studies have suggested that, through unknown mechanisms, ASPP2/ 53BP2L expression varies greatly between different cell types, 40 as well as within certain cells in a context-dependent manner. 22 In order to begin understanding the mechanisms controlling ASPP2/ 53BP2L expression, we examined the genomic sequence encompassing the cDNA start site of ASPP2/ 53BP2L . Three different computer algorithms independently predicted a promoter region within the 3.0 kB region surrounding the predicted transcription start site (TSS). [41] [42] [43] [44] Sequence analysis revealed a dense CpG island (0.98 probability score) (open boxes) encompassing the first exon (green sequence) and the predicted TSS ( þ 1), and multiple putative E2F-binding sites (underlined) 45, 46 ( Figure 1a ). Using the stringent contextual E2F SiteScan algorithm (performed for us by Dr Alexander Kel, Inst. of Cytology & Genetics, Novosibirsk, Russia), two of these E2F sites were further identified as high scoring sites (asterisks). 45 We also found phylogenetic conservation between human and mouse ASPP2 promoters (not shown). Together, the sequence is suggestive that this genomic region contains a promoter and that ASPP2/ 53BP2L has the features of an E2F target gene. 45 
ASPP2/ 53BP2L minimal basal promoter
Since the sequence analysis of the region encompassing the ASPP2/ 53BP2L putative TSS was predicted to contain a promoter region, we wished to functionally interrogate this region for the ability to activate transcription. We first identified a human BAC clone derived from chromosome 1 and containing the TP53BP2 locus. From this we isolated and sequenced a 3.3 kB genomic fragment from -2764 to þ 276 relative to the first exon start site, and cloned this into the pGL3-Basic luciferase reporter vector (Promega). After transfection into Saos-2 cells, this region stimulates the luciferase reporter at least a 20-fold relative to the empty vector -suggestive that an active promoter region is present within this region (Figure 1b) . To identify the minimal promoter region that could activate transcription, we generated a series of deletion mutants as shown schematically on the left-hand side of Figure 1b . Sequential deletions from the 5 0 direction to nucleotide -326 did not attenuate luciferase reporter activation, suggesting that regions downstream of -326 were capable of promoter activation. However, a 5 0 deletion to nucleotide -41 eliminates luciferase reporter activation. These results suggest that a region contained within nucleotides -326 to -41 is important for promoter activity. To test the extent to which other upstream or downstream elements cooperate with this region, we deleted nucleotides -163 to þ 90 from an ASPP2/ 53BP2L promoter spanning -1018 to þ 276 and likewise found significant attenuation of luciferase activity. Together, these results are consistent with the notion that a minimal basal ASPP2/ 53BP2L promoter is contained within this region although the possibility of control elements outside the genomic region used for these studies cannot be excluded.
The ASPP2/ 53BP2L promoter-luciferase reporter is stimulated by E2F-1 and serum
Since the ASPP2/ 53BP2L promoter sequence was typical of an E2F-regulated gene (Figure 1 ), we wished to determine whether our functional ASPP2/ 53BP2L promoter-reporter was stimulated by E2F as well as serum. Co-transfection of increasing amounts of E2F-1 expression vector with an ASPP2/ 53BP2L promoter-luciferase reporter (À1018 to þ 276) results in a dose-dependent increase in luciferase activation (Figure 2a) . However, neither transactivationincompetent E2F-1 (1-368) nor DNA-binding-incompetent E2F-1 (132E) could activate the ASPP2/ 53BP2L promoterreporter. We also investigated the ability of other E2F family members to stimulate the ASPP2/ 53BP2L promoter by cotransfecting E2F-1, E2F-2, E2F-3, and E2F-4 and DP1 expression vectors with the ASPP2/ 53BP2L promoter-reporter ( Figure 2b ) and found that the activating E2Fs (E2F-1-3) 28 could stimulate the ASPP2/ 53BP2L promoter compared to E2F-4 ( Figure 2b ). Equivalent expression of E2F-4 was confirmed by immunoblot (not shown). Consistent with these findings, after transfection of the ASPP2/ 53BP2L -promoter-reporter, increased luciferase activity is detected in cells grown in 10% serum, as compared to cells grown in 0.1% serum (Figure 2c ). Together, these results suggest that the ASPP2/ 53BP2L promoter is regulated by E2F.
E2F-1 expression stimulates endogenous ASPP2/ 53BP2L expression
Since E2F-1 most strongly stimulated the ASPP2/ 53BP2L promoter-reporter (Figure 2 ), we wondered if E2F-1 could activate endogenous ASPP2/ 53BP2L expression. To test this, we utilized a Saos-2 cell line containing an E2F-1 cDNA expression vector under the control of a tetracycline-regulated promoter. 30, 47 Addition of the tetracycline analogue doxycycline induced the expression of E2F-1 and an increase in endogenous ASPP2/ 53BP2L protein and mRNA levels ( Figure 3a) . To demonstrate that E2F-1 transcription function is required to induce endogenous ASPP2/ 53BP2L , we utilized tetracycline-regulated Saos-2 cell lines containing either a DNA-binding incompetent mutant E2F-1 (132E), or a mutant E2F-1 lacking the trans-activation domain (1-374). 47 Neither E2F-1 (132E) nor E2F-1 (1-374) was able to increase endogenous ASPP2/ 53BP2L (Figure 3b and c). To determine if ASPP2/ 53BP2L could be stimulated in different cell types, we infected HCT116p53À/À colorectal cancer cells with an adenovirus-E2F-1 expression vector and induced endogenous ASPP2/ 53BP2L mRNA over two-fold compared with infection with an adenovirus-GFP expression vector (data not shown). These results suggest that the endogenous ASPP2/ 53BP2L promoter is stimulated by E2F-1.
ASPP2/ 53BP2L expression is maximal in S-phase
Since ASPP2/ 53BP2L expression was controlled by E2F (Figures 2 and 3 ) and the activating E2Fs play roles in controlling late G1/early S-phase genes, 28, 48 we reasoned that ASPP2/ 53BP2L levels would vary throughout the cell cycle. To explore this possibility, we cultured HT1080 cells in 0.1% serum-containing media and found that ASPP2/ 53BP2L expression declined as cells exited the cell cycle and arrested at G0/G1 (Figure 4a and b) . However, upon release of the G0/ G1 arrest and re-entry into the cell cycle by culturing in 10% serum, we observed that ASPP2/ 53BP2L levels increased as cells transitioned from late G1 into early S-phase (Figure 4a and b). Consistent with these findings, increases in ASPP2/ 53BP2L levels were observed in a public microarray data set (http://genome-www5.stanford.edu/) generated from serum and mitogen-stimulated normal human lymphocytes compared to resting/unstimulated normal human lymphocytes ( Figure 4c ). 49 Since serum factors might also stimulate ASPP2/ 53BP2L expression independent of the cell cycle, it was necessary to also examine changes in ASPP2/ 53BP2L levels throughout the cell cycle independent of serum stimulation.
Cells were synchronized at the G1 boundary with hydroxyurea (HU) and, upon removal, ASPP2/ 53BP2L levels increased as cells entered S-phase ( Figure 5 ). Similar results were obtained in normal human diploid GM38 fibroblasts (not shown). These results suggest that ASPP2/ 53BP2L expression is cell cycle regulated with maximal expression in early Sphase, and are consistent with our findings that E2F regulates ASPP2/ 53BP2L . However, the existence of additional pathways that modulate ASPP2/ 53BP2L levels through serum or mitogenic factors remains possible. . Western blots (top panels) and Northern blots (bottom panels) for ASPP2/ 53BP2L on Saos2 cell lines that conditionally express (a) wt E2F-1, (b) E2F-1(132E), or (c) E2F-1 (1-374). Prior to induction, cell lines were maintained in 0.5% FBS containing media for 30 h and then induced with 2.0 mg/ml doxycycline, followed by collection at the indicated timepoints 0 direction suggest that a minimal promoter is contained within À326 to À41. Moreover, a dropout deletion from À163 to þ 90 implicates control elements possibly to þ 90, relative to the first ASPP2/ 53BP2L exon ( Figure 1b) . Sequence analysis from À326 to þ 90 reveals four putative E2F-binding sites, denoted as M1, M2, M3, and M4 in Figure 6a . Two sites, M1 and M3, were identified using the contextual E2F SiteScan algorithm and are denoted with asterisks. 45 In order to interrogate these putative E2F-binding sites for ability to influence ASPP2/ 53BP2L promoter activation, we changed the core nucleotide CG motif to AT in each binding site alone, or in combination (M1-4), and determined the differences in ASPP2/ 53BP2L promoter-reporter basal luciferase activity (Figure 6b ). Relative to basal promoter activity contained within the -326 to þ 276 ASPP2/ 53BP2L promoter-reporter, mutation at the M3 E2F site alone results in a greater than 10-fold stimulation of basal promoter activity. In contrast, mutagenesis at other individual putative E2F sites does not appreciably alter basal promoter activity, although mutation of all four sites modestly attenuates basal promoter activity.
Increases in basal promoter activity after mutation at specific E2F sites have been described with other E2F-regulated genes. 28, 48, [50] [51] [52] To determine if mutations at these E2F sites affect E2F-inducibility of the ASPP2/ 53BP2L promoter, we cotransfected increasing amounts of E2F-1 expression vector with the different E2F-binding site mutant ASPP2/ 53BP2L promoter-reporters (Figure 6c ). ASPP2/ 53BP2L promoterreporters harboring individual binding site mutations remained sensitive to E2F-1-induction in a dose-dependent manner, although the absolute induction of the M3 site mutant promoter was significantly higher because of the enhanced basal levels. In contrast, mutation of all four putative E2F sites in this promoter region (M1-4, Figure 6c ) significantly attenuates E2F-1 induction. Similarly, when the ASPP2/ 53BP2L promoter-reporter M1-4 (with all four putative E2F sites mutated) was assayed after serum starvation and release, luciferase activation was significantly attenuated compared to the wild-type ASPP2/ 53BP2L promoter-reporter (Figure 6d) . Together, these results support the notion that ASPP2/ 53BP2L is a direct E2F target gene, but that ASPP2/ 53BP2L regulation by E2F is complex, with different E2F sites potentially playing different roles -alone or in combination. (Figure 6c) , we reasoned that E2F-1 would bind the endogenous ASPP2/ 53BP2L promoter in its native chromatin context. To examine this, we performed a chromatin immunoprecipitation (ChIP) assay on the proximal ASPP2/ 53BP2L promoter region (Figure 7 ). ASPP2/ 53BP2L promoter-specific PCR primers amplify this region after chromatin IP with an anti-E2F-1-specific antibody, but not an irrelevant control antibody (anti-caspase 12), as shown in Figure 7a . To further demonstrate that this was a specific interaction, ASPP2/ 53BP2L -specific primers that amplify an upstream region that does not contain E2F-binding sites (control primers) cannot generate a PCR product after chromatin IP with anti-E2F-1-specific antibody (Figure 7a ). To further demonstrate the specificity of the E2F-1 DNAbinding interaction on the ASPP2/ 53BP2L endogenous promoter, we also performed chromatin IP with an anti-HA antibody on HCT116p53À/À cells transfected with an HA-tagged wildtype E2F-1 expression vector and successfully PCR amplified the ASPP2/ 53BP2L proximal promoter region (Figure 7b ). In contrast, no PCR product could be amplified after chromatin IP with anti-HA antibody from cells transfected with an HAtagged DNA-binding incompetent mutant E2F-1 (132E), nor from cells transfected with an HA-empty vector. Equivalent expression of transfected E2F-1 is shown on an anti-HA immunoblot in Figure 7b , bottom panel. These findings suggest that the ASPP2/ 53BP2L promoter, in its native chromatin context, can specifically bind E2F-1 protein, and is consistent with our data demonstrating that ASPP2/ 53BP2L is a direct E2F target gene.
Discussion
We have demonstrated that ASPP2/ 53BP2L is a direct E2F target gene utilizing complex mechanisms within the proximal promoter region. Given that ASPP2/ 53BP2L may play an important role in modulating sensitivity to apoptotic signals at least in part through stimulation of p53 family member apoptotic function, 19, [21] [22] [23] our findings that ASPP2/ 53BP2L is downstream of the Rb/E2F pathway suggests a previously undescribed link between these two important tumor suppressor pathways.
Our data underscore the complex nature of ASPP2/ 53BP2L regulation that has been previously suggested, 22 and now provides mechanistic insight into an upstream pathway controlling ASPP2/ 53BP2L transcription. First, the ASPP2/ 53BP2L promoter has typical features suggestive of an E2F target (Figure 1) . Second, expression of E2F family members 1, 2, and 3 can stimulate an ASPP2/ 53BP2L promoter-luciferase reporter (Figure 2 ) as well as endogenous ASPP2/ 53BP2L levels, at least when tested with E2F-1 in the latter example (Figure 3) . Third, mutation of the four E2F-binding sites in the proximal promoter region (-326 to þ 276) significantly attenuates E2F-1 induction of the ASPP2/ 53BP2L promoter-luciferase reporter (Figure 6c) , as well as serum induction (Figure 6d ). This suggests that these E2F sites cooperate for full E2F-1-induced activation at the ASPP2/ 53BP2L promoter since individual mutations at these sites do not attenuate E2F-1 induction. We also noted that mutation at E2F site M3 results in a dramatic increase in ASPP2/ 53BP2L basal promoter activity (Figure 6b ), as has been described for many E2F-regulated genes. This suggests de-repression, for example, due to loss of E2F-4/5-p130 repressor complexes, 28, 48, [50] [51] [52] although whether such regulation also occurs with ASPP2/ 53BP2L remains to be experimentally tested. Finally, we found that endogenous E2F-1 could bind the endogenous ASPP2/ 53BP2L proximal promoter in its native chromatin context, and that wild-type E2F-1, but not DNA-binding incompetent E2F-1(132E), binds the ASPP2/ 53BP2L promoter ( Figure 7 ). Taken together, these results strongly suggest that ASPP2/ 53BP2L is an E2F target gene and that the E2F DNA-binding sites contained within -326 to þ 276 play an important role in regulating ASPP2/ 53BP2L . However, the precise contributions of the different E2F sites contained within this region -alone or in combination -and which specific roles the various E2F family members may play in controlling ASPP2/ 53BP2L induction remain to be elucidated. Moreover, we cannot exclude that other E2F response elements may also be important for regulating ASPP2/ 53BP2L outside the -326 to þ 276 promoter region.
Our observations also imply that other non-E2F-mediated upstream pathways are involved in regulating ASPP2/ 53BP2L transcription. Although ASPP2/ 53BP2L expression is cell cycle regulated with maximal expression at early S-phase as is typical for E2F-regulated genes (Figures 4 and 5) , we cannot exclude that additional mitogen-induced regulation by serum factors could also be important, since the ASPP2/ 53BP2L promoter is stimulated by serum (Figures 2c and 6d) . Mutation of all four E2F sites in the ASPP2/ 53BP2L minimal promoter (À326 to þ 276) significantly attenuates serum-induced promoter activation, suggesting that the combination of these E2F sites is important for mediating serum responsiveness (Figure 6d) . However, the basal activity of this mutated minimal promoter in the presence of 10% serum still remains significantly elevated compared to empty vector control, implying that other cis-acting control elements are also involved in regulating ASPP2/ 53BP2L . Studies interrogating the ASPP2/ 53BP2L promoter to further define other upstream regulatory pathways are underway.
In this report, we focus on the transcriptional control of ASPP2/ 53BP2L by E2F as this places ASPP2/ 53BP2L in a central role linking the Rb/E2F and p53 family member pathways. However, given that ASPP2/ 53BP2L is a potent modulator of cellular apoptotic thresholds, 19, 22, 23 it is likely that multiple mechanisms are important for controlling ASPP2/ 53BP2L levels. Interestingly, the proteins encoded by the two TP53BP2 mRNA splice variants, ASPP2 or 53BP2L (long), and BBP or 53BP2S (short), 20, 53 have different abilities to promote p53-mediated apoptosis: ASPP2/ 53BP2L has more potent proapoptotic function than BBP/ 53BP2S . 19 Thus, mechanisms regulating these different splice variants may have a profound influence on biologic outcomes. Likewise, posttranslational mechanisms may also play important roles in controlling ASPP2/ 53BP2L function. 22, 54 However, details of such potential mechanisms remain to be explored. Nevertheless, the paradigm that both transcriptional and posttranscriptional mechanisms can play cell context-dependent roles in controlling proapoptotic gene products has been described, such as is the case for E2F-1. 4, 29, [55] [56] [57] To what extent cell context influences E2F regulation of ASPP2/ 53BP2L remains to be determined. Intriguingly, as described in the accompanying report, ASPP1 is also regulated by E2F. Although both ASPP2/ 53BP2L and ASPP1 can stimulate transcription function of the p53 family members, 23 they also appear to have distinct functions. 19 Moreover, ASPP2/ The functional implication of E2F regulating both ASPP2/ 53BP2L and ASPP1 remains to be elucidated but underscores the complexity of the E2F-ASPP pathway.
In the majority of human tumors, deregulation of the Rb/E2F pathway (e.g. such as by loss of Rb, overexpression of D-type cyclins, or loss of p16
INK4
) releases E2F activity, resulting in both unrestrained proliferation as well as promotion of apoptosis via p53-dependent and p53-independent mechanisms -at least in tumors that have not disabled the apoptotic pathway.
3-5 E2F-1 protein is also stabilized in response to damage to promote apoptotic function through complex and incompletely understood mechanisms.
29,55,57-60 E2F-1 can lower the apoptotic threshhold by directly activating death machinery genes such as caspases, Apaf-1 and BH3-only proteins [61] [62] [63] [64] in addition to directly activating p73. 37, 38 Our finding that ASPP2/ 53BP2L is an E2F target gene provides the basis for a working model of a common linkage between the Rb/E2F and p53/p73 apoptotic pathways independent of the ARF-MDM2 axis (Figure 8 ). Consistent with the notion that ASPP2/ 53BP2L may play a role in tumorigenesis and chemotherapy sensitivity, ASPP2/ 53BP2L (and ASPP1) expression is frequently silenced in breast cancers, 19 and low ASPP2/ 53BP2L expression trends towards a poor clinical outcome in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy. 65 Although the precise role of the E2F-ASPP2/ 53BP2L pathway in mediating cell death sensitivity remains to be elucidated, our results nevertheless open new avenues for investigation into the molecular mechanisms linking two important tumor suppressor pathways. Therapies designed to exploit these pathways by enhancing E2F-ASPP2/ 53BP2L apoptosis may ultimately prove useful in the oncology clinic. 
Materials and Methods
Cloning of the ASPP2/ 53BP2L promoter and plasmids A human BAC clone (RP11-332L18) derived from chromosome 1 containing the TP53BP2 locus (BACPAC Resources) was used to PCR amplify different regions from À2764 to þ 276 relative to the ASPP2/ 53BP2L cDNA start site. 19, 20 PCR products were subcloned into the pCR2.1-TOPO vector (Invitrogen) and then cloned into the pGL3-Basic luciferase vector (Promega) using standard restriction endonuclease digestion and DNA ligation. Primer sequences used were: (À2764 to þ 276) forward 5 0 -gaagagggagctaaatgatgag-3 0 ; reverse 5
0 ; reverse 5 0 -tcgcccacttaccggcatcatc-3 0 . pGL3 (À1018 to þ 276) was generated by HindIII digest and religation of pGL3 (À1530 to þ 276). pGL3 (DÀ163 to þ 90) was generated by SmaI digest and religation of pGL3 (À1018 to þ 276). pGL3 (À41 to þ 276) was generated by ApaI digest and religation of pGL3 (À1018 to þ 276). The different site mutations were generated in the pGL3 (À326 to þ 276) vector with the Promega GeneEditor system according to manufacturer-specified protocols. All resultant constructs were sequence verified. The mutation oligonucleotide sequences were as follows:
M1 : 
Luciferase-reporter assays
Cells grown to 60% confluence in six-well plates were transfected with the specified ASPP2/ 53BP2L luciferase reporter plasmid, together with specified E2F expression vector at the indicated amount, pRSV b-gal expresssion vector (0.1 mg), as well as with the appropriate amount of empty plasmid vector, to give a total of 1 mg plasmid DNA per transfection. Transfections were performed with FuGENE 6 reagent per manufacture protocol (Roche). At 36 h post-transfection, cells were harvested for luciferase assays as described previously. 66 Briefly, cells were collected into ice-cold 0.1 M K 2 PO 4 , 1 mM DTT (pH 7.8) buffer, freeze/thawed three times in liquid nitrogen, centrifuged at 10 000 Â g Â 20 min at 41C, and supernatants collected. Luciferase activity was assayed in 10 mM luciferin, glygly buffer (25 mM glygly, 15 mM MgSO 4 , 10 mM ATP, pH 7.5), with an AutoLumatB953. Relative luciferase light units were normalized to b-gal activity determined by incubating 20 ml lysate with 20 ml b-gal reaction buffer (1 mg/ml CPRG, 50 mM K 2 PO 4 (pH 7.8), 1 mM MgCl 2 ) for 20 min at 371C and reading absorbance at 570 nm.
Western blotting
Total cellular lysates were prepared and quantitated as described previously, 22 resolved on SDS-6% SDS-PAGE, transferred to PVDF membrane, blocked with 5% nonfat milk, probed with the specified primary antibody, followed by HRP-conjugated secondary antibody, and then visualized with enhanced chemiluminescence (Pierce SuperSignal) and Xray film using standard techniques. Anti-ASPP2/ 53BP2L mouse monoclonal antibody was from BD-BioSciences, anti-E2F-1 antibodies were from Santa Cruz (C-20) or from NeoMarkers (KH20), anti-HSP70 antibody was a gift from Dr. Louie Naumovski (Stanford University), anti-tubulin and anti-HA antibodies were from Sigma. HRP-conjugated secondary antibodies were from Jackson.
Quantitative RT-PCR
TaqMan real-time PCR was performed as described previously 65 with minor modifications. Briefly, total RNA was isolated with the RNAeasy kit (Qiagen) and reverse transcribed using the High-Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA, USA) as reported. 67 Expression of mRNA for ASPP2/ 53BP2L and 18S endogenous control was measured in each specimen with real-time PCR using the Applied Biosystems Assayson-Demandt Gene Expression Product and 18S endogenous control kit (P/N 4319413) on an ABI PRISM s 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA). For calibration and generation of standard curves, we used HCT116 cDNA. All reactions were carried out in triplicate with minimal Ct variability seen, with a variance of 0.14. ASPP2/ 53BP2L signal was normalized to an 18S signal and the relative expression of ASPP2/ 53BP2L across samples was determined by the ASPP2/ 53BP2L /18S ratio from each sample relative to the calibrator RNA sample derived from HCT116 cells. Northern blots were performed as described previously. 22 
Chromatin immunoprecipitation (ChIP)
ChIP analysis on HCT116p53À/À cells was performed as described, 66 with minor modifications. Briefly, cells were crosslinked with 1% formaldehyde solution in PBS Â 15 min and then stopped with 0.125 M glycine Â 5 min. Cells were then lysed in 5 ml of lysis buffer (150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris (pH 8.0), 5 mM EDTA) with protease inhibitors (10 mg/ml each of PMSF, leupeptin, and pepstatin) and lysates sonicated on ice to yield chromatin fragments of approximately 600-1000 nucleotides. Debris was removed by centrifugation at 13 000 Â g Â 10 min and extract pre-cleared with 50 ml of protein Asepharose/salmon sperm DNA slurry (1 : 1) for 30 min at 41C. In all, 2 mg of anti-E2F1 antibody (Santa Cruz), 2 mg of control antibody (anti-caspase 12), or 2 mg of anti-HA antibody was incubated with precleared supernatants overnight at 41C. A volume of 50 ml of protein A/G-agarose slurry was added and incubated for 2 h at 41C. Beads were washed twice with ice-cold RIPA buffer, four times with ice-cold IP wash buffer (100 mM Tris (pH 8.0), 500 mM LiCl, 1% NP-40, 1% deoxycholic acid), and twice more with ice-cold RIPA buffer. IP elution buffer (150 ml; 50 mM NaHCO 3 , 1% SDS, freshly made) was added and rocked for 15 min at RT, and the beads spun out and supernatant collected. Another 150 ml IP elution buffer was added to the beads as before and supernatants combined. To reverse the formaldehyde crosslinking, 1 ml of 10 mg/ml RNase A and 12 ml of 5 M NaCl were added and incubated at 651C Â 6 h. DNA fragments were purified by phenol-chloroform extraction, ethanol precipitation, and dissolved in 100 ml of nH 2 O. PCR amplification of specific ASPP2/ 53BP2L promoter sequence was performed with 25 cycles (941C for 15 s; 651C for 45 s), and the product analyzed on a 2% TAE-agarose gel stained with ethidium bromide. ASPP2/ 53BP2L -specific primers used were: (À60 to þ 145) forward primer: 
Flow cytometry
Cells were fixed and stained with propidium iodide and analyzed on a Becton Dickinson FACScan as described previously. 22 Cell cycle analysis was performed using ModFitLT Software (Verity).
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Note added in proof
For this report, we designated the 5 0 -end of the published ASPP2/ 53BP2L cDNA (Samuels-Lev et al. 19 ) as the putative transcription start. After our manuscript went to press, it was pointed out to us that Fogal and Lu (this issue) designated the putative transcription start site 55 bp upstream of the published sequence based on an unpublished EST in the database (gl 30774493). Therefore, although the nomenclature of these two reports differs slightly, the conclusions remain completely unchanged.
